Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Planck, Maria ^a   Edlund, Karolina ^b   Botling, Johan ^b   Micke, Patrick ^b   Isaksson, Sofi ^a   Staaf, Johan ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ARTICLE; CANCER STAGING; CHROMOSOME 12P; CHROMOSOME 16P; CHROMOSOME 1P; CHROMOSOME 21Q; CHROMOSOME 5Q; CHROMOSOME 6Q; CHROMOSOME 7Q; CHROMOSOME 8P; CHROMOSOME 9P; CONTROLLED STUDY; COPY NUMBER VARIATION; EGFR GENE; FEMALE; GENDER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE K RAS; PROMOTER REGION; SMOKING;

ADENOCARCINOMA; DNA COPY NUMBER VARIATIONS; FEMALE; GENES, RAS; GENOMICS; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION, GENETIC;

EID: 84886258227     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078614     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, (Eds.) (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. doi:10.1056/NEJMoa040938. PubMed: 15118073.
4. Pao W, Chmielecki J, (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760-774. doi:10.1038/nrc2947. PubMed: 20966921.
5. Kadara H, Kabbout M, Wistuba II, (2011) Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 17: 50-65. PubMed: 22040022.
6. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, et al. (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18: 378-381. doi:10.1038/nm.2658. PubMed: 22327623.
7. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703. doi:10.1056/NEJMoa1006448. PubMed: 20979469.
8. Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, et al. (2008) Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 214: 347-356. doi:10.1002/path.2267. PubMed: 17992665.
9. Broët P, Dalmasso C, Tan EH, Alifano M, Zhang S, et al. (2011) Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res 17: 3542-3550. doi:10.1158/1078-0432.CCR-10-2185. PubMed: 21521776.
10. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, et al. (2009) An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28: 2773-2783. doi:10.1038/onc.2009.135. PubMed: 19525976.
11. Fong Y, Lin YS, Liou CP, Li CF, Tzeng CC, (2010) Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. Respirology 15: 700-705. doi:10.1111/j.1440-1843.2010.01746.x. PubMed: 20409020.
12. Newnham GM, Conron M, McLachlan S, Dobrovic A, Do H, et al. (2011) Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer 11: 93. doi:10.1186/1471-2407-11-93. PubMed: 21385341.
13. Reinmuth N, Jauch A, Xu EC, Muley T, Granzow M, et al. (2008) Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer 62: 193-201. doi:10.1016/j.lungcan.2008.03.011. PubMed: 18450321.
14. Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, et al. (2007) Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Sci 98: 985-991. doi:10.1111/j.1349-7006.2007.00483.x. PubMed: 17459062.
15. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, et al. (2005) Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 11: 6177-6185. doi:10.1158/1078-0432.CCR-05-0293. PubMed: 16144918.
16. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, et al. (2006) Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 24: 1679-1688. doi:10.1200/JCO.2005.03.8224. PubMed: 16549822.
17. Yuan S, Yu SL, Chen HY, Hsu YC, Su KY, et al. (2011) Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. J Clin Oncol 29: 3435-3442. doi:10.1200/JCO.2011.35.3979. PubMed: 21810691.
18. Blons H, Pallier K, Le Corre D, Danel C, Tremblay-Gravel M, et al. (2008) Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med Genomics 1: 25. doi:10.1186/1755-8794-1-25. PubMed: 18549475.
19. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, et al. (2006) Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 24: 5079-5090. doi:10.1200/JCO.2005.05.1748. PubMed: 17075127.
20. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, et al. (2012) Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLOS ONE 7: e36530. doi:10.1371/journal.pone.0036530. PubMed: 22590557.
21. Staaf J, Isaksson S, Karlsson A, Jönsson M, Johansson L, et al. (2012) Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int J Cancer 1: 2020-2031. PubMed: 23023297.
22. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, et al. (2009) Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 27: 2793-2799. doi:10.1200/JCO.2008.19.7053. PubMed: 19414676.
23. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, et al. (2012) Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 22: 1197-1211. doi:10.1101/gr.132662.111. PubMed: 22613842.
24. Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres J, et al. (2012) A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res 18: 5606-5616. doi:10.1158/1078-0432.CCR-12-0505. PubMed: 22914773.
25. Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, et al. (2012) Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis and tissue microarray validation. Clin Cancer Res 19: 194-204. PubMed: 23032747.
26. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, et al. (2012) Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 72: 100-111. doi:10.1158/1538-7445.AM2012-100. PubMed: 22080568.
27. Micke P, Edlund K, Holmberg L, Kultima HG, Mansouri L, et al. (2011) Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J Thorac Oncol 6: 1833-1840. doi:10.1097/JTO.0b013e3182295917. PubMed: 22011649.
28. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, et al. (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12: R41. doi:10.1186/1465-6906-12-S1-P41. PubMed: 21527027.
29. Staaf J, Lindgren D, Vallon-Christersson J, Isaksson A, Göransson H, et al. (2008) Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays. Genome Biol 9: R136. doi:10.1186/gb-2008-9-9-r136. PubMed: 18796136.
30. Popova T, Manié E, Stoppa-Lyonnet D, Rigaill G, Barillot E, et al. (2009) Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol 10: R128. doi:10.1186/gb-2009-10-11-r128. PubMed: 19903341.
31. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193. doi:10.1093/bioinformatics/19.2.185. PubMed: 12538238.
32. Gene Expression Omnibus. Available: http://www.ncbi.nlm.nih.gov/geo/.
33. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, et al. (2009) A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489-500. doi:10.1016/j.ccr.2009.03.022. PubMed: 19477428.
34. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2: 62ra93. PubMed: 21160078.
35. Kono SA, Marshall ME, Ware KE, Heasley LE, (2009) The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Update 12: 95-102. doi:10.1016/j.drup.2009.05.001. PubMed: 19501013.
36. Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, et al. (2013) Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC. Mol Cancer Res 11: 759-767. doi:10.1158/1541-7786.MCR-12-0652. PubMed: 23536707.
37. Nakanishi H, Matsumoto S, Iwakawa R, Kohno T, Suzuki K, et al. (2009) Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas. Cancer Res 69: 1615-1623. doi:10.1158/0008-5472.CAN-08-3218. PubMed: 19190329.
38. Staaf J, Jönsson G, Ringnér M, Baldetorp B, Borg A, (2011) Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 13: R129. doi:10.1186/bcr3075. PubMed: 22169037.
39. Ha G, Roth A, Lai D, Bashashati A, Ding J, et al. (2012) Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res 22: 1995-2007. doi:10.1101/gr.137570.112. PubMed: 22637570.
40. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, et al. (2005) An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37: 48-55. PubMed: 15608639.
41. Lara R, Mauri FA, Taylor H, Derua R, Shia A, et al. (2011) An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis. Oncogene 30: 3513-3521. doi:10.1038/onc.2011.61. PubMed: 21423205.
42. Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, et al. (2007) Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol 8: R201. doi:10.1186/gb-2007-8-9-r201. PubMed: 17894889.
43. Kitamura M, Kasai A, (2007) Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. Cancer Lett 252: 184-194. doi:10.1016/j.canlet.2006.11.015. PubMed: 17189671.
44. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, et al. (2008) Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLOS ONE 3: e1651. doi:10.1371/journal.pone.0001651. PubMed: 18297132.
45. Bossé Y, Postma DS, Sin DD, Lamontagne M, Couture C, et al. (2012) Molecular signature of smoking in human lung tissues. Cancer Res 72: 3753-3763. doi:10.1158/0008-5472.CAN-12-1160. PubMed: 22659451.
46. Planck M, Isaksson S, Veerla S, Staaf J, (2013) Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS-wild type lung adenocarcinoma reveals gene signatures associated with patient outcome. Clin Cancer Res: [Epub ahead of print].
47. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698. doi:10.1158/1078-0432.CCR-05-1492. PubMed: 16361555.
48. Byers LA, Diao L, Wang J, Saintigny P, Girard L, et al. (2013) An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19: 279-290. doi:10.1158/1078-0432.CCR-12-1558. PubMed: 23091115.
49. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, et al. (2005) Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561-5570. doi:10.1158/0008-5472.CAN-04-4603. PubMed: 15994928.
50. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, et al. (2009) Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16: 463-474. doi:10.1016/j.ccr.2009.10.016. PubMed: 19962665.
51. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898. doi:10.1038/nature06358. PubMed: 17982442.
52. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905. doi:10.1038/nature08822. PubMed: 20164920.
53. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, et al. (2009) Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119: 1727-1740. doi:10.1172/JCI37127. PubMed: 19451690.
54. Huang YT, Lin X, Chirieac LR, McGovern R, Wain JC, et al. (2011) Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer. PLOS ONE 6: e22961. doi:10.1371/journal.pone.0022961. PubMed: 21829676.
55. GlaxoSmith, Kline Cancer Cell Line Genomic Profiling Data. Accessed 2013 9/23. Available: https://cabig.nci.nih.gov/tools/caArray_GSKdata.
56. Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, et al. (2010) Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev 19: 2590-2597. doi:10.1158/1055-9965.EPI-10-0332. PubMed: 20802022.
57. The Cancer Genome Atlas. Available: http://cancergenome.nih.gov/.
58. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873. doi:10.1038/nature09208. PubMed: 20668451.
59. Job B, Bernheim A, Beau-Faller M, Camilleri-Broët S, Girard P, et al. (2010) Genomic aberrations in lung adenocarcinoma in never smokers. PLOS ONE 5: e15145. doi:10.1371/journal.pone.0015145. PubMed: 21151896.